Gubra (GUBRA) Stock Overview
A biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GUBRA Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Gubra A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 448.00 |
| 52 Week High | DKK 748.00 |
| 52 Week Low | DKK 318.40 |
| Beta | 0.60 |
| 1 Month Change | 6.82% |
| 3 Month Change | 26.91% |
| 1 Year Change | -26.56% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 307.27% |
Recent News & Updates
Recent updates
Gubra A/S' (CPH:GUBRA) 35% Jump Shows Its Popularity With Investors
Jun 28
AbbVie Agreement And Clinical Trials Will Unlock New Avenues
Strategic partnerships and collaborations with top pharma companies ensure sustainable revenue streams and growth opportunities for Gubra.We're Not Worried About Gubra's (CPH:GUBRA) Cash Burn
May 04Gubra A/S' (CPH:GUBRA) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Mar 11We're Not Very Worried About Gubra's (CPH:GUBRA) Cash Burn Rate
Jan 14Gubra A/S' (CPH:GUBRA) Shares Climb 25% But Its Business Is Yet to Catch Up
Jun 19Subdued Growth No Barrier To Gubra A/S (CPH:GUBRA) With Shares Advancing 60%
Mar 07Shareholder Returns
| GUBRA | DK Life Sciences | DK Market | |
|---|---|---|---|
| 7D | 17.9% | 2.4% | 3.3% |
| 1Y | -26.6% | -0.1% | -33.5% |
Return vs Industry: GUBRA underperformed the Danish Life Sciences industry which returned -5.2% over the past year.
Return vs Market: GUBRA exceeded the Danish Market which returned -34.4% over the past year.
Price Volatility
| GUBRA volatility | |
|---|---|
| GUBRA Average Weekly Movement | 7.2% |
| Life Sciences Industry Average Movement | 5.6% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 9.6% |
| 10% least volatile stocks in DK Market | 2.5% |
Stable Share Price: GUBRA's share price has been volatile over the past 3 months compared to the Danish market.
Volatility Over Time: GUBRA's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Danish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 275 | Markus Rohrwild | www.gubra.dk |
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology.
Gubra A/S Fundamentals Summary
| GUBRA fundamental statistics | |
|---|---|
| Market cap | DKK 7.32b |
| Earnings (TTM) | DKK 1.75b |
| Revenue (TTM) | DKK 2.64b |
Is GUBRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUBRA income statement (TTM) | |
|---|---|
| Revenue | DKK 2.64b |
| Cost of Revenue | DKK 96.02m |
| Gross Profit | DKK 2.54b |
| Other Expenses | DKK 794.73m |
| Earnings | DKK 1.75b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 27, 2026
| Earnings per share (EPS) | 106.86 |
| Gross Margin | 96.36% |
| Net Profit Margin | 66.22% |
| Debt/Equity Ratio | 0% |
How did GUBRA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/14 16:02 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Gubra A/S is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rune Dahl | DNB Carnegie |
| Jesper Ilsøe | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |